Developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and National Institute of Virology, Covaxin got the nod for human clinical trials from the Drugs Controller General of India last month. Besides Covaxin, another experimental shot developed by Zydus Cadila has also begun human clinical trials.
Earlier this week, AIIMS, Delhi, administered the first dose of Covaxin to a 30-year-old man. Even as Phase 1 human trials of Biotech’s Covaxin India’s first indigenous Covid-19 vaccine candidate, are on at most of the 12 sites selected by ICMR across the country, the Post-Graduate Institute of Medical Sciences, Rohtak, has claimed “encouraging” results from first part of the tests. According to CTRI, the Covaxin phase I and II trials are expected to take one year and three months.
